Cargando…
The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards?
Stem cell-based clinical interventions are increasingly advancing through preclinical testing and approaching clinical trials. The complexity and diversity of these approaches, and the confusion created by unproven and untested stem cell-based “therapies,” create a growing need for a more comprehens...
Autores principales: | Barker, Roger A., Carpenter, Melissa K., Forbes, Stuart, Goldman, Steven A., Jamieson, Catriona, Murry, Charles E., Takahashi, Jun, Weir, Gordon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995446/ https://www.ncbi.nlm.nih.gov/pubmed/29742388 http://dx.doi.org/10.1016/j.stemcr.2018.04.010 |
Ejemplares similares
-
Lessons learnt, and still to learn, in first in human stem cell trials
por: Barker, Roger A., et al.
Publicado: (2022) -
What Does CLARITY-BPA Mean for Canadians?
por: Rogers, Lindsay D.
Publicado: (2021) -
Final NIH Policy on the Use of a Single Institutional Review Board for Multisite Research
por: Gordon, VM, et al.
Publicado: (2017) -
Flawed Ethics Recommendations of the U.S. EPA’s Human Studies Review
Board
por: Shrader-Frechette, Kristin
Publicado: (2007) -
How Can Institutional Review Boards Best Interpret Preclinical
Data?
por: Lavery, James V.
Publicado: (2011)